People: Galena Biopharma Inc (GALE.PH)

GALE.PH on Philadelphia Stock Exchange

2.59USD
22 May 2013
Price Change (% chg)

$0.08 (+3.19%)
Prev Close
$2.51
Open
$2.62
Day's High
$2.63
Day's Low
$2.58
Volume
4,300
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Sanford Hillsberg

 63 2007 Chairman of the Board

Mark Ahn

 49 2011 President, Chief Executive Officer, Director

Ryan Dunlap

 42 2012 Director - Finance, Controller, Principal Accounting Officer

Mark Schwartz

 57 2011 Chief Operating Officer, Executive Vice President

Rosemary Mazanet

 57 2012 Executive Vice President and Chief Medical Officer

William Ashton

 2013 Director

Richard Chin

 46 2009 Independent Director

Stephen Galliker

 65 2007 Independent Director

Steven Kriegsman

 71 2006 Independent Director

Rudolph Nisi

 80 2009 Independent Director
» Insider Trading

Biographies

Name Description

Sanford Hillsberg

 Mr. Sanford J. Hillsberg.,J.D., has been Chairman of the board of Directors of Galena Biopharma, Inc since 2007. Mr. Hillsberg has been an attorney with TroyGould PC since 1976 and is a member of the firm’s Management Committee. Mr. Hillsberg was a founder and until December 2007, served as a director and Secretary of ImmunoCellular Therapeutics, Ltd., a publicly-held biopharmaceutical company formed to develop cellular therapies, including dendritic cell-based vaccines for the treatment of brain and other cancers, and its predecessor company since February 2004. Mr. Hillsberg served as a director and Secretary of Duska Therapeutics, Inc., a publicly-held biopharmaceutical company, and its predecessor company from 1999 until January 2006. He previously served as a director and Vice President of Medco Research, Inc., a then publicly-held pharmaceutical company. Mr. Hillsberg is a member of the Board of Governors of Cedars-Sinai Medical Center and has also previously served as a Commissioner of the Quality and Productivity Commission of the City of Los Angeles. Mr. Hillsberg holds a B.A. degree from the University of Pennsylvania and a J.D. degree from Harvard Law School.

Mark Ahn

 Dr. Mark J. Ahn, Ph.D., has been appointed as the President, Chief Executive Officer, Director of Galena Biopharma, Inc. He has served as President and Chief Executive Officer since March 31, 2011 and as a director since 2007 and has served since September 2011 as the President, Chief Financial Officer and sole director of RXi Pharmaceuticals Corporation subsidiary, which the company refer to as “RXi.” Dr. Ahn is also an adjunct Professor, Biosciences at Creighton University. He brings more than 20 years of experience in the biopharmaceutical industry. Prior to joining Galena, starting in 2011, Dr. Ahn was Principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies and an Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Professor and Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to joining Hana, he served as Vice President, Hematology and corporate officer at Genentech, Inc., and held positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr. Ahn also serves on public and venture capital-backed board of directors for RXi Pharmaceuticals, Access Pharmaceuticals, Mesynthes and ScribesSTAT. Dr. Ahn is the author of over 50 peer reviewed journal articles and books. Dr. Ahn received a B.A. and M.B.A. from Chaminade University; and M.A. from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.

Ryan Dunlap

 Mr. Ryan Dunlap has been appointed as Director - Finance, Controller, Principal Accounting Officer of Galena Biopharma, Inc., effective July 16, 2012. From June 2008 to June 2012, Mr. Dunlap served as Senior Manager, Business Assurance of Moss Adams, LLP, where he provided assurance and consulting services with a focus on technology and life sciences. From 2007 to 2008, Mr. Dunlap served as Director, Financial Accounting of Vestas American Wind Technology, Inc., a private company that engages in the sale and service of wind turbines in North America, and is a subsidiary of Vestas Wind Systems A/S, a public company that engages in the manufacture and sale of wind turbines and wind power systems globally. Prior to that, from 2005 to 2007, Mr. Dunlap served as Senior Manager, Business Assurance of KPMG, LLP, where he provided external audit and business advisory services to emerging and established public and private, and international and domestic entities. Mr. Dunlap has also been the Project Lead, Corporate Audit from 2002 to 2005 of Nike, Inc., where he planned and executed several operational and financial internal audits of various regions and business units. Mr. Dunlap is a certified public accountant and holds a degree in accounting from the University of Oregon.

Mark Schwartz

 Dr. Mark W. Schwartz, Ph.D., has been appointed as Chief Operating Officer, Executive Vice President of RXi Pharmaceuticals Corporation effective April 13, 2011. Dr. Schwartz joined Galena as part of acquisition of Apthera where he had been the President and Chief Executive Officer since January 2010. Prior to joining Apthera, Dr. Schwartz served for five years as President and Chief Executive Officer of Bayhill Therapeutics Inc., a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases, where he completed a partnership with Genentech for the development of the company’s type 1 diabetes vaccine. He had also served as President and Chief Executive Officer of Calyx Therapeutics, Inc., as well as positions of increasing responsibilities at DuPont, Trega Biosciences and Incyte Genomics. Dr. Schwartz is on the advisory board of BayBio, is a past board member of the Biotechnology Industry organization (BIO), and is on the faculty of the San State University in their Master of Biotechnology Program.

Rosemary Mazanet

 Dr. Rosemary Mazanet, M.D., Ph.D., has been appointed as Executive Vice President and Chief Medical Officer of Galena Biopharma Inc., effective May 3, 2012. Dr. Mazanet has served as the Chief Medical Officer of company on a part-time basis since February 2012. She is a life sciences investment professional and executive with management and drug development experience. She has been a partner at Apelles Investment Management, LLC since 2009, and the President of Rosemary Mazanet LLC, a private consulting firm in the life sciences, since 2004. Prior to that, Dr. Mazanet was a General Partner, Director of Research and CSO of Oracle Partners, LP, a health care hedge fund. Dr. Mazanet received her M.D. and Ph.D. from the University of Pennsylvania School of Medicine (where she is a Member of the Penn Medicine Board of Trustees and Executive Committee for the Health System), and trained in Internal Medicine at the Brigham and Women’s Hospital and Oncology at the Dana Farber Cancer Institute, both in Boston. Dr. Mazanet led Clinical Development teams in Oncology and Infectious Disease at Amgen, Inc. from 1993 to 1998, and has also served as the CEO of several life sciences companies including Breakthrough Therapeutics, LLC, and Access Pharmaceuticals. She has served as a Director for numerous public and private companies.

William Ashton

 Mr. William L. Ashton has been appointed as Director of Galena Biopharma, Inc., effective April 26, 2013. Mr. Ashton is a senior executive with more than twenty-eight years of experience in biotechnology and pharmaceutical leadership and management. Most recently, at Amgen, Inc., he served as Vice President of corporate and government affairs and Vice President of sales, and was directly responsible for product launches, as well as key government agencies including Centers for Medicare and Medicaid Services, Office of Inspector General, General Accounting Office, Office of Management and Budget, and MedPAC. After retiring from Amgen, Mr. Ashton joined the University of the Sciences in Philadelphia where he currently serves as Associate Provost and Senior Vice President of Strategic Business Development, Founding Dean, Mayes College of Healthcare Business and Policy, and Assistant Professor of Pharmaceutical Business. Mr. Ashton is on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine (NIH), and a commissioner for the Medical Representatives National Certificate Commission. He currently serves on the board of Sucampo Pharmaceuticals. He received his Bachelor of Science from California University of Pennsylvania and his Master of Science from the University of Pittsburgh.

Richard Chin

 Dr. Richard Chin, M.D., is Independent Director of Galena Biopharma, Inc since 2009. Dr. Chin is a physician with expertise in drug development. He has overseen multiple Investigational New Drug Applications (INDs) and New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a textbook on clinical trial medicine. Dr. Chin is a biotech entrepreneur. Most recently, starting in 2008, Dr. Chin was the CEO of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, engaged in developing drugs for neglected diseases in impoverished countries. OneWorld Health became part of PATH in December of 2012. From 2006 to 2008, he was the CEO and President of OXiGENE. From 2004 to 2006, Dr. Chin was at Elan Corporation, where he served, among other roles, as Senior Vice President of Global Development. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. between 1999 and 2004, including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California. He is currently on the Adjunct Faculty of UCSF Medical School, and serves on the board of directors of several biotechnology companies.

Stephen Galliker

 Mr. Stephen S. Galliker, CPA, serves as Independent Director of Galena Biopharma, Inc since 2007. Mr. Galliker served as the Executive Vice President, Finance and Administration, and Chief Financial Officer of Dyax Corp., a biopharmaceutical company focused on advancing novel biotherapeutics for unmet medical needs, from 1999 until his retirement in July 2008. From 1996 to 1999, Mr. Galliker was the Chief Financial Officer of Excel Switching Corporation, a developer and manufacturer of open switching platforms for telecommunications networks, and was Excel’s Vice President, Finance and Administration from 1997 to 1999. From 1992 to 1996, Mr. Galliker was employed by Ultracision, Inc., a developer and manufacturer of ultrasonically powered surgical instruments, where he served as Chief Financial Officer and Vice President of Finance until 1995, when he became Ultracision’s Chief Operating Officer. Mr. Galliker is also a director of Mitomics, Inc. Incorporated, a privately owned medical device company. Mr. Galliker was also a director of Osteotech, Inc., a medical device company, until its merger into Medtronic, Inc. in November, 2010. Mr. Galliker is a Certified Public Accountant and received a B.S. from Georgetown University and an M.B.A. from the University of Chicago.

Steven Kriegsman

 Mr. Steven A. Kriegsman has been Independent Director of Galena Biopharma, Inc. Mr. Kriegsman has been a director and the President and Chief Executive Officer of CytRx Corporation since July 2002. He previously served as Director and Chairman of Global Genomics from June 2000. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences, and Maxim Pharmaceuticals. Mr. Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors’ College. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the company since has been sold). In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association.

Rudolph Nisi

 Dr. Rudolph Nisi, M.D., is Independent Director of Galena Biopharma, Inc. Dr. Nisi has held various positions at New York Westchester Square Medical Center (NYWSMC). In addition to having been on the Active Staff in Internal Medicine/Cardiology since 1963, Dr. Nisi was also Director of Medicine since 1975, Chief of Cardiology since 1975, Chairman of Medical Critical Care Unit since 1975, President of the Medical Board from 1977 to 1978, Chairman of the Board of Trustees since 1983 and from 1976 to 1978, Chairman of the ER Committee since 1984, and Vice-President of Medical Affairs since 1993. In 2011, Dr. Nisi retired as Chairman of the board of directors at NYWSMC and now currently holds the position of Vice Chairman. Dr. Nisi was the Chairman of the board of Medco Research Inc. Dr. Nisi has also served as an Attending Physician at New York Hospital, a Clinical Assistant Professor of Medicine at Cornell University Medical College and an Assistant Dean at Weill Medical College of Cornell University. Dr. Nisi has also served as a director of Tempra Technology, Inc., a thermal research and development company, since 1997 and on the boards of Touchtone HMO and New York Presbyterian Hospital. Dr. Nisi holds a B.S. degree from Fordham University and a Doctor of Medicine degree from the University of Rome Medical School in Rome, Italy and is a fellow in the American College of Cardiology. Dr. Nisi is also a graduate of the Director’s college at Stanford University.

Basic Compensation

Name Fiscal Year Total

Sanford Hillsberg

 --

Mark Ahn

 1,148,770

Ryan Dunlap

 --

Mark Schwartz

 568,327

Rosemary Mazanet

 --

William Ashton

 --

Richard Chin

 --

Stephen Galliker

 --

Steven Kriegsman

 --

Rudolph Nisi

 --
As Of 30 Dec 2011

Insider Trading

Name Shares Traded Price

DUNLAP RYAN

 1,246 $1.30

AHN MARK J

 7,668 $1.30

SCHWARTZ MARK W

 7,668 $1.30

HILLSBERG SANFORD JAY

 20,000 $0.00

SCHWARTZ MARK W

 21,902 $0.40

AHN MARK J

 31,289 $0.40

SCHWARTZ MARK W

 89,322 $0.00

HILLSBERG SANFORD JAY

 31,966 $0.00

SCHWARTZ MARK W

 12,924 $0.40

AHN MARK J

 31,289 $0.40

LEE KWANG

 5,000 $0.60

AHN MARK J

 10,000 $0.66

KHVOROVA ANASTASIA

 76,923 $0.00
» Full list on Insider Trading
Search Stocks